Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

MDS 2023 | Benefits and drawbacks of the IPSS-M

Ciro Rinaldi • 5 May 2023
MDS 2023
Myelodysplastic Syndromes

Ciro Rinaldi, MD, PhD, Lincoln County Hospital, Lincoln, UK, discusses the benefits and limitations of the new Molecular International Prognostic Scoring System (IPSS-M). Whilst the tool is user-friendly and the integration of molecular markers from next-generation sequencing (NGS) panels allows to provide a more accurate prognosis and follow-up for each patient, access to NGS panels is limited. This interview took place at the 17th International Congress on Myelodysplastic Syndromes 2023 (MDS 2023) held in Marseille, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Ciro Rinaldi

1:12
The potential of targeting mutant calreticulin with antibodies in MPNs
Ciro Rinaldi • 3 Jun 2023
0:58
The potential of CAR-T therapy targeting mutant CALR in myelofibrosis & essential thrombocythemia
Ciro Rinaldi • 3 Jun 2023
1:31
HMA combination strategies in MDS: BLC2, CD47 & TIM-3 inhibitors
Ciro Rinaldi • 5 May 2023
1:16
The rationale for combining magrolimab with ruxolitinib in myelofibrosis
Ciro Rinaldi • 5 May 2023

Related Videos

2:22
Haplo-SCT for older patients with AML/MDS, and should age be a barrier to transplantation?
Raynier Devillier • 15 Apr 2024
2:31
Emerging treatment options for patients with ESA-refractory MDS: luspatercept & imetelstat
Eva Hellström-Lindberg • 11 Apr 2024
1:49
The unmet needs of patients with VEXAS syndrome
Maël Heiblig • 17 Apr 2024
1:25
The role of the bone marrow microenvironment in hematological malignancies
Manja Wobus • 17 Apr 2024
The content of VJHemOnc is intended for healthcare professionals